🔍

NEOGEN - Neogen Chemicals

📊 NSE: NEOGEN 🏢 Chemicals 📅 Last Updated: 12/14/2025 10:27

📢 Recent Corporate Announcements

Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 07 Mar 2026, 04:08 PM

Neogen Chemicals' board has approved the issuance of 10 lakh equity shares at a price of Rs 1,610 per share, totaling Rs 161 crore. The shares are being issued on a preferential basis to Cadamba Solutions Private Limited, a promoter group entity. This issue price represents a significant 17.02% premium over the regulatory floor price of Rs 1,375.82. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to seek shareholder approval for this capital infusion.

Issuance of 1,000,000 equity shares at Rs 1,610 each, aggregating to Rs 161 crore
The issue price is 17.02% higher than the SEBI-calculated floor price of Rs 1,375.82
The entire allotment is directed to Cadamba Solutions Private Limited, part of the promoter group
Post-allotment, the allottee will hold a 3.65% stake in the company
Extraordinary General Meeting (EGM) set for March 29, 2026, with a record date of March 20, 2026

💡 Investors should view this as a positive signal as the promoters are increasing their stake at a significant premium to the floor price. Monitor the company's subsequent announcements regarding the specific utilization of these funds for growth or debt reduction.

Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoters

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 07 Mar 2026, 03:57 PM

Neogen Chemicals has announced an Extra Ordinary General Meeting (EGM) on March 29, 2026, to seek approval for a preferential issue of equity shares. The company plans to issue 10,00,000 shares to Cadamba Solutions Private Limited, a promoter group entity, at a price of Rs. 1,610 per share. This transaction will result in a total capital infusion of Rs. 161 crores into the company. The relevant date for determining the floor price was set as February 27, 2026, and the cut-off date for voting eligibility is March 20, 2026.

Preferential allotment of 10,00,000 equity shares to promoter group entity Cadamba Solutions Private Limited.
Issue price fixed at Rs. 1,610 per share, including a premium of Rs. 1,600 per share.
Total fundraise amount of Rs. 161 crores to be received as 100% cash consideration.
EGM scheduled for March 29, 2026, with remote e-voting available from March 26 to March 28, 2026.
The capital infusion is subject to SEBI and stock exchange approvals following recent inter-se promoter transfers.

💡 Investors should view this promoter-led capital infusion as a strong signal of confidence in the company's long-term growth. The non-debt funding will strengthen the balance sheet and support future expansion plans.

Neogen Chemicals to Raise ₹161 Crore via Preferential Issue to Promoter Group

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 07 Mar 2026, 03:47 PM

Neogen Chemicals has convened an Extra Ordinary General Meeting (EGM) on March 29, 2026, to approve a preferential issue of equity shares. The company intends to issue 10,00,000 shares to Cadamba Solutions Private Limited, a member of the promoter group. The shares are priced at ₹1,610 each, including a premium of ₹1,600, resulting in a total fund infusion of ₹161 crore. This capital injection by the promoters indicates strong internal confidence in the company's future growth prospects.

Issuance of 10,00,000 equity shares at a fixed price of ₹1,610 per share.
Total capital raise amounting to ₹161 crore from promoter group entity Cadamba Solutions Private Limited.
Relevant date for floor price determination set as February 27, 2026, in accordance with SEBI ICDR regulations.
EGM scheduled for March 29, 2026, to seek shareholder approval via special resolution.
The allotment is subject to a lock-in period as per SEBI regulations and requires specific regulatory exemptions due to prior inter-se transfers.

💡 Investors should view the promoter's capital infusion at a significant premium as a positive signal of long-term commitment. Monitor the EGM results and subsequent disclosures regarding the specific utilization of these funds for expansion or debt reduction.

Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 07 Mar 2026, 02:09 PM

Neogen Chemicals' board has approved the issuance of 10 lakh equity shares at a price of Rs 1,610 per share, aggregating to Rs 161 crore. The shares are being issued to Cadamba Solutions Private Limited, a promoter group entity, which will hold a 3.65% stake post-allotment. Significantly, the issue price is at a 17.02% premium over the regulatory floor price of Rs 1,375.82. An Extra Ordinary General Meeting (EGM) is scheduled for March 29, 2026, to obtain shareholder approval for the transaction.

Issuance of 10,00,000 equity shares at Rs 1,610 per share, totaling Rs 161 crore
Issue price is 17.02% higher than the SEBI-mandated floor price of Rs 1,375.82
Allottee is Cadamba Solutions Private Limited, a member of the promoter group
Post-allotment, the allottee will hold a 3.65% stake in the company
EGM for shareholder approval is set for March 29, 2026, with a record date of March 20, 2026

💡 Investors should take confidence from the promoter group's decision to infuse capital at a significant premium to the floor price. This move strengthens the balance sheet and indicates strong internal backing for the company's growth prospects.

Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue at Rs 1,610 Per Share

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 07 Mar 2026, 02:07 PM

Neogen Chemicals has approved a preferential issue of 10 lakh equity shares to Cadamba Solutions Private Limited, a promoter group entity. The issue is priced at Rs 1,610 per share, which is a significant 17.02% premium over the SEBI-mandated floor price of Rs 1,375.82. This move will result in a total capital infusion of Rs 161 crore into the company. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to seek shareholder approval for this transaction.

Issuance of 10,00,000 equity shares at a price of Rs 1,610 per share
Total fundraise amount aggregates to Rs 161 crore
Issue price is 17.02% higher than the regulatory floor price of Rs 1,375.82
Allottee is Cadamba Solutions Private Limited, belonging to the Promoter Group
Post-allotment, the allottee will hold a 3.65% stake in the company

💡 Investors should take note of the promoter group's commitment to infuse capital at a premium to the floor price, which signals strong internal confidence. Monitor the EGM outcome and subsequent updates on how the capital will be deployed for growth initiatives.

Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group at Rs 1,610/Share

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 07 Mar 2026, 02:04 PM

Neogen Chemicals' board has approved the issuance of 10 lakh equity shares to Cadamba Solutions Private Limited, a promoter group entity, on a preferential basis. The shares are priced at Rs 1,610 each, representing a significant 17.02% premium over the SEBI-mandated floor price of Rs 1,375.82. This capital infusion will aggregate to Rs 161 crore and result in the allottee holding a 3.65% stake in the company post-allotment. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to obtain shareholder approval for the transaction.

Issuance of 10,00,000 equity shares at a price of Rs 1,610 per share (including Rs 1,600 premium).
Total fundraise amount aggregates to Rs 161 crore from promoter group entity Cadamba Solutions Private Limited.
Issue price is 17.02% higher than the regulatory floor price of Rs 1,375.82.
Post-allotment, the promoter group entity will hold a 3.65% stake in the company.
EGM for shareholder approval is set for March 29, 2026, with a record date of March 20, 2026.

💡 Investors should view this as a strong signal of promoter confidence, as the capital is being infused at a premium to the floor price. The funds will likely strengthen the balance sheet for future expansion or debt management.

Neogen Chemicals Q3 FY26 Revenue Up 9% to ₹220 Cr; Plans ₹150 Cr Promoter Fundraise

🔵 WATCH ⭐ 8/10

EARNINGS 📅 18 Feb 2026, 01:29 PM

Neogen Chemicals reported a 9% YoY revenue growth to ₹220 crore in Q3 FY26, driven by a 35% surge in the inorganic chemicals segment. While gross margins expanded by 150 bps, PAT remained suppressed at ₹4 crore due to high interest costs and transient expenses related to the Neogen Ionics ramp-up. The company is on track to commission its rebuilt Dahej plant in Q1 FY27 and has secured a ₹150 crore preferential equity infusion from promoters. Additionally, a strategic JV with Japan's Morita Investment is progressing with a $20 million incoming investment for battery material production.

Q3 FY26 revenue grew 9% YoY to ₹220 crore, with inorganic chemicals growing 35% to ₹33 crore.
Net profit stood at ₹4 crore, impacted by ₹1,175 crore consolidated net debt and front-loaded expansion costs.
Board approved a ₹150 crore preferential share issue to promoters to provide financial flexibility for growth.
Insurance claim of ₹251.12 crore is pending, with ₹60 crore expected immediately and the bulk by March 2026.
Battery materials division (Neogen Ionics) contributed ₹12 crore; Pakhajan project on track for FY27 production.

💡 Investors should monitor the timely commissioning of the Dahej and Pakhajan facilities and the receipt of insurance claims to deleverage the balance sheet. The promoter's ₹150 crore infusion is a positive signal of confidence despite current margin pressures from expansion.

Neogen Chemicals Discloses Audio Recording of Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 06:50 PM

Neogen Chemicals Limited has released the audio recording of its Earnings Conference Call held on February 12, 2026. The call was conducted at 2:00 p.m. IST to discuss the company's financial results and business outlook with analysts and investors. This disclosure is a standard regulatory requirement under Regulation 30 of the SEBI Listing Regulations. The recording is now available for public access on the company's official website.

Earnings Conference Call for analysts and investors held on February 12, 2026, at 2:00 p.m.
Audio recording of the session has been hosted on the company's website for transparency.
Compliance filing submitted under Regulation 30 of SEBI (LODR) Regulations, 2015.
The filing serves as a routine update following the announcement of periodic financial results.

💡 Investors should listen to the recording to understand management's commentary on growth guidance and operational performance. No immediate action is required as this is a routine compliance filing.

Neogen Chemicals Receives Rs 60 Cr Insurance Payout; Total Recovery Reaches Rs 140 Cr

🔵 WATCH ⭐ 7/10

OTHER 📅 12 Feb 2026, 06:48 PM

Neogen Chemicals has received a third on-account insurance payment of Rs 60 Crore following the fire incident at its Dahej SEZ facility in March 2025, bringing total recoveries to Rs 140 Crore. The company has recognized a consolidated loss of Rs 362.90 Crore but expects to recover Rs 348.82 Crore through insurance, resulting in a net impact of only Rs 14.08 Crore. While the affected MPP3 plant remains suspended, a replacement facility is scheduled for commissioning in Q1 FY27. To mitigate earnings impact, the company has shifted critical production to other sites and is leveraging its Patancheru plant expansion.

Received Rs 60 Crore as the third on-account insurance payment, totaling Rs 140 Crore to date.
Consolidated loss recognized at Rs 362.90 Crore against an expected insurance recovery of Rs 348.82 Crore.
Net financial impact on the company estimated at Rs 14.08 Crore on a consolidated basis.
Replacement plant construction is underway with a target commissioning date of Q1 FY27.
Production of critical specialty products shifted to other sites and Patancheru plant to minimize earnings impact.

💡 Investors should monitor the execution timeline for the replacement plant scheduled for Q1 FY27 and the company's ability to maintain margins while operating from alternative sites. The steady inflow of insurance claims is a positive sign for liquidity and asset recovery.

Neogen Chemicals Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 05:09 PM

Neogen Chemicals Limited has informed the stock exchanges that the audio recording of its earnings conference call held on February 12, 2026, is now available for public access. The call, which took place at 2:00 p.m., provided a platform for management to discuss the company's financial performance and future outlook with analysts and investors. This disclosure is part of the company's routine compliance under SEBI Listing Regulations. Investors can access the recording via the company's official website to gain deeper insights into operational trends.

Earnings conference call held on February 12, 2026, at 2:00 p.m. IST
Audio recording hosted on the company's website as per SEBI Regulation 30
Direct link to recording provided: https://neogenchem.com/wp-content/uploads/ecr003.mp3
Disclosure submitted to both BSE and NSE for transparency

💡 Investors should listen to the recording to understand management's commentary on the specialty chemicals market and the progress of their lithium-ion battery materials segment. No immediate action is required as this is a routine administrative filing.

Neogen Chemicals Releases Audio Recording of Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 05:07 PM

Neogen Chemicals Limited has officially released the audio recording of its Earnings Conference Call held on February 12, 2026. The call followed the company's latest financial results announcement, providing management insights into operational performance and future outlook. The recording is accessible on the company's website under the investor relations section for all stakeholders. This disclosure is a mandatory regulatory requirement under SEBI's Regulation 30 to ensure transparency.

Earnings conference call conducted on February 12, 2026, at 02:00 p.m. IST
Audio recording link: https://neogenchem.com/wp-content/uploads/ecr003.mp3
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Disclosure facilitates access to management commentary for those who missed the live session

💡 Investors should listen to the recording to understand management's perspective on recent performance and specific guidance on the specialty chemicals segment.

Neogen Chemicals Q3 FY26 Revenue up 9% to ₹220 Cr; PAT drops 63% on Transitory Costs

🔵 WATCH ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 12:14 AM

Neogen Chemicals reported a 9% YoY growth in consolidated revenue to ₹220 crore for Q3 FY26, supported by steady demand in organic and inorganic chemicals. However, consolidated PAT plummeted 63% to ₹3.7 crore, primarily due to elevated interest costs (₹21.5 crore), higher insurance premiums following a fire incident, and pre-operative expenses for the battery chemicals division. The company is executing a massive ₹1,500 crore CAPEX plan for Neogen Ionics, targeting peak revenues of up to ₹2,950 crore by FY29. To support this growth, the Board has approved a ₹150 crore preferential issue to the Promoter Group.

Consolidated Revenue increased 9% YoY to ₹220 crore, while Standalone Revenue grew 8% to ₹215.6 crore.
Consolidated PAT declined 63% YoY to ₹3.7 crore due to a 60% surge in interest costs and fire-related operational headwinds.
Neogen Ionics (Battery Chemicals) reported ₹12 crore in revenue for Q3 FY26, with the Pakhajan Greenfield project on track for H1 FY27.
The company has received ₹83.48 crore in insurance claims so far, with a net receivable of ₹251.12 crore still pending.
Board approved a ₹150 crore preferential equity issue to promoters to reinforce the company's capital base for expansion.

💡 Investors should focus on the commissioning timelines of the Pakhajan plant in FY27 and the normalization of interest costs as insurance payouts are received. While current profitability is under pressure, the long-term growth trajectory in the battery chemicals segment and promoter backing remain key positive triggers.

Neogen Chemicals Q3 Revenue Up 9% to ₹220 Cr; Plans ₹150 Cr Fundraise via Promoters

🔵 WATCH ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 12:12 AM

Neogen Chemicals reported a 9% YoY revenue growth to INR 220 crore in Q3 FY26, driven by volume growth in organic and inorganic chemicals. While consolidated PAT rose 63% to INR 4 crore, profitability was weighed down by finance costs and transitory expenses related to the Dahej plant fire and battery chemical expansions. The company is raising INR 150 crore from promoters to fuel growth and has formed a strategic JV with Japan's Morita Investment for lithium salt production. Progress on the Pakhajan Greenfield project remains on track for commissioning in FY27.

Consolidated Revenue grew 9% YoY to INR 220 crore; Standalone PAT stood at INR 9 crore
Board approved raising up to INR 150 crore through a preferential issue to the Promoter Group
Received INR 83.48 crore in insurance claims for the Dahej fire; net receivable remains at INR 251.12 crore
Formed an 80:20 JV with Japan’s Morita Investment for global LiPF6 salt production
Pakhajan Electrolyte plant nearing mechanical completion with commercial production expected in H1 FY27

💡 Investors should monitor the progress of the Pakhajan facility and the recovery of insurance claims, which are expected to normalize interest costs. The promoter-led fundraise and Japanese JV signal strong long-term confidence in the battery materials segment.

Neogen Chemicals Q3 FY26 Revenue Up 9% to ₹220 Cr; PAT Drops 63% on Fire-Related Costs

🔵 WATCH ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 12:10 AM

Neogen Chemicals reported a 9% YoY revenue growth in Q3 FY26, reaching ₹220 crore, driven by volume growth in organic and inorganic chemicals. However, net profit (PAT) plummeted by 63% to ₹3.7 crore due to transitory costs from a Dahej plant fire, higher interest expenses, and pre-operative spends for the battery chemicals division. The company is aggressively expanding its battery materials segment with a ₹1,500 crore capex plan and a new JV with Japan's Morita Investment for LiPF6 salt. Management expects insurance recoveries in FY27 and significant revenue contributions from the Pakhajan project starting H1 FY27.

Consolidated Revenue grew 9% YoY to ₹220 crore in Q3 FY26, while 9M FY26 revenue reached ₹615.4 crore.
Net Profit (PAT) declined sharply by 63% YoY to ₹3.7 crore, impacted by ₹21.5 crore interest costs and fire-related overheads.
Board approved a ₹150 crore preferential equity issue to promoters to fund growth initiatives.
Finalized an 80:20 JV with Japan's Morita Investment for global LiPF6 electrolyte salt production.
Total planned Capex of ₹1,500 crore targets a peak revenue potential of up to ₹2,950 crore by FY29.

💡 Investors should monitor the commissioning of the Pakhajan plant in H1 FY27 and the recovery of insurance claims, which are critical for margin normalization. The stock remains a long-term play on the EV battery supply chain, though near-term profitability is under pressure from high finance costs.

Neogen Chemicals Q3 Net Profit Drops 39% YoY to ₹8.77 Cr Despite 7.6% Revenue Growth

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 08:16 PM

Neogen Chemicals reported a mixed performance for Q3 FY26, with revenue from operations growing 7.6% YoY to ₹215.60 crore. However, net profit saw a sharp decline of 39.1% YoY to ₹8.77 crore, primarily driven by a 74.8% surge in finance costs which reached ₹22.85 crore. The company is still recovering from the March 2025 fire at its Dahej SEZ plant, having received ₹80 crore in insurance payments to date. While operating margins remained stable at 17%, the increased debt burden and interest expenses are significantly weighing on the bottom-line profitability.

Revenue from operations increased to ₹215.60 crore in Q3 FY26 from ₹200.41 crore in Q3 FY25.
Net profit declined to ₹8.77 crore compared to ₹14.41 crore in the corresponding quarter of the previous year.
Finance costs spiked significantly to ₹22.85 crore from ₹13.07 crore YoY, reflecting higher borrowing costs.
The company has received ₹80 crore in on-account insurance payments for the Dahej plant fire loss as of December 2025.
Operating margin stood at 17%, while the net profit margin contracted to 4% from 7% YoY.

💡 Investors should be cautious as rising finance costs and debt levels are eroding the benefits of revenue growth. Monitor the progress of the remaining insurance claims and the company's ability to deleverage its balance sheet in the coming quarters.

View All NEOGEN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 13% YoY to INR 777.6 Cr in FY25, driven by healthy volumes in the base business and BuLi Chem. Neogen Ionics contributed INR 12 Cr in its first year. Standalone revenue rose 10% to INR 773.7 Cr. However, Q2 FY26 consolidated revenue growth slowed to 8% (INR 208.7 Cr) due to the temporary suspension of the Dahej plant.

Geographic Revenue Split

Not explicitly disclosed in percentages, but the company reports a global distribution network supporting export growth and is strategically diversifying into stable geographies to mitigate regional economic downturns.

Profitability Margins

FY25 Standalone PAT margin improved to 6.26% from 5.86% (a 7% increase). Consolidated PAT for Q2 FY26 dropped 69% YoY to INR 3.4 Cr, with PAT margins contracting by 405 bps to 1.6% due to elevated operating costs and interest expenses following the Dahej fire incident.

EBITDA Margin

FY25 Standalone EBITDA margin grew 240 bps to 19.0% (INR 147.1 Cr). In Q2 FY26, consolidated EBITDA margins fell 349 bps to 14.4% (INR 30.0 Cr) due to higher insurance premiums, increased job work costs, and performance-linked employee incentives.

Capital Expenditure

Neogen recently raised INR 253 Cr to fund large-scale capex. Ongoing investments include the organic Dahej SEZ plant rebuild and battery business expansion. The company is also utilizing INR 200 Cr from NCDs and INR 65 Cr in unsecured loans to support these initiatives.

Credit Rating & Borrowing

CRISIL maintains a 'Negative' outlook due to liquidity pressure. Standalone debt rose sharply to INR 722 Cr in Q2 FY26 (Net Debt INR 595 Cr). Interest coverage stood at 2.56x in FY25 but faced pressure in Q2 FY26 as interest costs rose 53% YoY to INR 19.5 Cr.

⚙️ Operational Drivers

Raw Materials

Key materials include Lithium salts, Bromine, and various chemical intermediates. While specific % of total cost per material is not disclosed, raw material price fluctuations and oversupply-led weak pricing significantly impacted FY25 margins.

Import Sources

Sourced from multiple suppliers across different global regions to ensure supply chain resilience; specific countries are not listed but the strategy emphasizes vendor diversification.

Key Suppliers

Not disclosed by name; however, the company utilizes a procurement team to manage long-term relationships with multiple regional suppliers to secure cost-effective materials.

Capacity Expansion

Current operations include plants at Mahape (Navi Mumbai), Karakhadi (Vadodara), and Dahej. The Dahej SEZ organic plant is undergoing a rebuild following a fire, with resumption planned for FY27. Future revenue targets of INR 950-1,000 Cr are based on current installed capacity.

Raw Material Costs

Inventory turnover improved 22% to 2.25 in FY25, indicating better material movement. Procurement strategies focus on maintaining adequate inventory levels to hedge against price volatility in chemical intermediates.

Manufacturing Efficiency

Operating leverage from higher volumes contributed to a 27% EBITDA growth in FY25. Manufacturing efficiency is supported by R&D-led process improvements and strategic job work to maintain volumes during plant outages.

Logistics & Distribution

Not disclosed as a specific percentage of revenue, but logistical disruptions are cited as a key business risk being monitored quarterly.

📈 Strategic Growth

Expected Growth Rate

10%

Growth Strategy

Neogen targets INR 1,150 Cr revenue by FY28 through a 'double-digit' growth trajectory. Strategy includes: 1) Expanding the battery chemicals business (Lithium salts/electrolytes), 2) Increasing focus on high-margin Pharmaceutical and Custom Manufacturing (CSM) segments to offset Agrochemical cyclicality, and 3) Leveraging the BuLi Chem integration for customer cross-selling.

Products & Services

Specialty chemicals, Lithium salts, Electrolytes for Lithium-ion batteries, Bromine-based compounds, and Inorganic chemicals used in Pharma and Agrochemicals.

Brand Portfolio

Neogen Chemicals, BuLi Chem, Neogen Ionics.

New Products/Services

Locally sourced electrolytes and lithium salts for the EV battery chain; expected to bolster the business risk profile as the battery business ramps up.

Market Expansion

Expansion into the Lithium-ion battery sector and deepening penetration in the Japanese market through Neogen Chemicals Japan Corporation.

Market Share & Ranking

Not disclosed in percentage, but described as having a 'first-mover advantage' in the Indian electrolyte and lithium salt manufacturing space.

Strategic Alliances

Joint Venture: Dhara Fine Chem Industries; Subsidiaries: Neogen Ionics Limited and Neogen Chemicals Japan Corporation Limited.

🌍 External Factors

Industry Trends

The industry is shifting toward Lithium-ion battery localization in India. Neogen is positioning itself as a key supplier of electrolytes to capture this growth, moving away from a heavy reliance on traditional Agrochemical cycles.

Competitive Landscape

Faces intense global competition, particularly from cheap imports that lead to price volatility.

Competitive Moat

Moat is built on: 1) Technical expertise in complex Bromine and Lithium chemistry, 2) Long-term R&D track record (20+ years), and 3) High switching costs in the CSM and Pharma segments due to rigorous quality approvals.

Macro Economic Sensitivity

Highly sensitive to global chemical pricing and demand; FY25 performance was impacted by sluggish global demand despite volume growth.

Consumer Behavior

Shift toward Electric Vehicles (EVs) is driving demand for Neogen's new battery chemical portfolio.

Geopolitical Risks

Geopolitical disruptions and policy changes in key markets are monitored quarterly; these factors currently impact supply chain costs and logistics.

⚖️ Regulatory & Governance

Industry Regulations

Adheres to IND AS accounting standards and stringent safety protocols for chemical manufacturing. Operations are subject to environmental and pollution control board norms.

Environmental Compliance

Maintains zero effluent discharge deviations and monitors compliance through daily checks and quarterly safety audits.

Taxation Policy Impact

Effective tax rate for FY25 was approximately 25% (INR 19.5 Cr PBT vs INR 5.8 Cr Tax in Standalone).

Legal Contingencies

Not disclosed in absolute INR values, but the company tracks litigations through weekly compliance checklists and consults external legal experts for contract vetting.

⚠️ Risk Analysis

Key Uncertainties

1) Fire and operational accidents (Dahej incident caused INR 14.1 Cr loss), 2) Volatility in Lithium prices impacting battery segment margins, 3) Elongated working capital cycles.